Overview

Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.

Status:
Completed

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether Ingavirin ® dosed 30 mg daily is effective and safe in the treatment of influenza and other acute respiratory viral infections in the course of standard therapy in 3-6 years old patients.

Phase:

Phase 3

Details

Lead Sponsor:

Valenta Pharm JSC

Collaborator:

Atlant Clinical Ltd.

Treatments:

Pentanedioic acid imidazolyl ethanamide